AGER and cholestasis: In view of its efficacy in preclinical studies of other inflammatory diseases, the RAGE inhibitors Azeliragon or FPS-ZM1 might have the potential to be used as pharmacological tools in treating cholestasis or cholestasis-associated fibrosis.